三诺生物收盘下跌2.13%，滚动市盈率40.52倍，总市值128.64亿元

Company Overview - Sanofi Biological Co., Ltd. closed at 22.96 yuan, down 2.13%, with a rolling PE ratio of 40.52 times and a total market value of 12.864 billion yuan [1] - The company specializes in the production and sales of blood glucose monitoring systems and related products, including blood lipid testing systems and blood pressure monitors [1] - Sanofi has received multiple accolades, including "National Enterprise Technology Center" and "National Engineering Research Center" [1] Financial Performance - In the first quarter of 2025, the company achieved operating revenue of 1.042 billion yuan, a year-on-year increase of 2.76% [1] - The net profit for the same period was 72.1151 million yuan, reflecting a year-on-year decrease of 10.90% [1] - The sales gross margin stood at 48.69% [1] Industry Comparison - The average PE ratio for the medical device industry is 55.28 times, with a median of 38.06 times, placing Sanofi at the 80th position in the industry ranking [1][2] - The company's PE ratio is lower than the industry average but higher than the median, indicating potential valuation concerns [2] - The average market value of the industry peers is 11.543 billion yuan, with Sanofi's market value at 12.864 billion yuan [2] Shareholder Information - As of March 31, 2025, Sanofi had 16,418 shareholders, an increase of 3,390 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]